Related Experiment Video

Updated: Jul 4, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Mild cognitive impairment in Parkinson's disease: the challenge and the promise

Hubert H Fernandez1, Gregory P Crucian, Michael S Okun

  • 1Department of Neurology, University of Florida, Gainesville, FL, USA. Fernandez@neurology.ufl.edu

Neuropsychiatric Disease and Treatment
|June 24, 2008
PubMed

Insights

Mild cognitive impairment (MCI) in Parkinson's disease (PD) is a recognized condition. This review proposes a definition and guidelines for its clinical and research evaluation.

Area of Science:

  • Neurology
  • Neuroscience
  • Cognitive Science

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder.
  • Mild cognitive impairment (MCI) is increasingly recognized in PD patients.
  • Understanding the overlap between PD and MCI is crucial for patient care.

Purpose of the Study:

  • To review the existing literature on Parkinson's disease and mild cognitive impairment.
  • To discuss the neuropsychological, pharmaceutical, and pathological connections.
  • To propose an operating definition and research guidelines for MCI in PD.

Main Methods:

  • Literature review of studies on PD and MCI.
  • Analysis of neuropsychological, pharmaceutical, and pathological data.
  • Synthesis of findings to establish a consensus.

Main Results:

  • Mild cognitive impairment (MCI) is a distinct feature in Parkinson's disease (PD).
  • There is significant overlap in pathology and clinical presentation between PD and MCI.
  • Current clinical criteria for MCI in PD are lacking.

Conclusions:

  • MCI in PD is a valid clinical and research entity.
  • An inclusive operating definition for MCI in PD is proposed.
  • Guidelines for future research and treatment evaluation are suggested.
Keywords:
Parkinson’s, dementiacognitionmild cognitive impairmenttherapy

More Related Videos

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...